Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check4 days agoChange DetectedThe study record shows the status updated to Terminated on 2026-07-28 with a Business Reason indicating no longer looking for participants, replacing the prior Completed status.SummaryDifference0.2%

- Check11 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This reflects a new entry in the study page's revision history.SummaryDifference0.1%

- Check18 days agoChange DetectedThe study record now indicates completion and recruitment is closed. Enrollment has ended and no new participants will be enrolled.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, representing a minor update to the site. No user-facing content changes are indicated in the provided context.SummaryDifference0.0%

- Check39 days agoChange Detected- Revision label updated from v3.6.0 to v3.6.2, indicating a new page build. The change does not modify study content or data displayed on the page.SummaryDifference0.0%

- Check54 days agoChange DetectedNew help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention label was updated from 'Intervention / Treatment' to 'Intervention/Treatment'. Recruitment status was updated to 'No longer looking for participants' and the site revision footer changed from v3.5.5 to v3.6.0.SummaryDifference0.3%

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.